Boundless Bio (BOLD) Stock Price, News & Analysis

Company Overview

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Key Stats

• Today's Range: $1.40 to $1.44
• 50-Day Range: $1.13 to $1.63
• 52-Week Range: $0.96 to $1.68
• Volume: 141,117 shs
• Average Volume: 59,703 shs
• Market Capitalization: $31.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Boundless Bio Stock Analysis - MarketRank™

Boundless Bio scored higher than 62% of companies evaluated by MarketBeat, and ranked 422nd out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Boundless Bio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Boundless Bio has a consensus price target of $4.00, representing about 185.2% upside from its current price of $1.40.

Amount of Analyst Coverage

Boundless Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Boundless Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Boundless Bio is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Boundless Bio has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of Boundless Bio has been sold short.

Short Interest Ratio / Days to Cover

Boundless Bio has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Boundless Bio has recently decreased by 76.68%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Boundless Bio does not currently pay a dividend.

Dividend Growth

Boundless Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Boundless Bio has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Boundless Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.10% of the stock of Boundless Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Boundless Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 6/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: PHARMACEUTICAL PREPARATIONS
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BOLD
• CIK: 0001782303
• Web: www.boundlessbio.com
• Phone: (858) 766-9912
• Fax: N/A
• Employees: 64
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Boundless Bio: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +183.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -53.60%
• Return on Assets: -34.66%

Debt

• Debt-to-Equity Ratio: 0.52
• Current Ratio: 9.87
• Quick Ratio: 9.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.41 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 22,460,000
• Free Float: 17,275,000
• Market Cap: $31.67 million
• Optionable: No Data
• Beta: 0.60